Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODENZA: Patient Preference Between ODM-201 and Enzalutamide in mCRPC
NCT03314324Phase 2Completed
- Sponsor
- Gustave Roussy
- Start
- Nov 2017
- Primary completion
- Jan 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of darolutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Gustave Roussy. Started Nov 2017; status: completed.
02
Drugs
darolutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03314324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03314324.